First patient in the USA to be treated with denovoSkin from CUTISS

In the USA, the first patient has been treated with the biotechnologically produced dermo-epidermal skin graft denovoSkin developed by CUTISS. The four-year-old boy suffered from complex scars and contractures following the healing of extensive skin burns, CUTISS reported in a press release. According to her, the patient has already survived two transplants with denovoSkin.

The skin graft developed by CUTISS is produced biotechnologically from a small biopsy of the patient's healthy skin. It should therefore make the large-scale removal of the patient's healthy skin for transplants superfluous. In contrast to conventional, cultivated epithelial autografts, denovoSkin consists not only of a top layer of skin, but has a two-layered dermo-epidermal structure.

The operation now being carried out in the USA is more than just a technology application, CUTISS CEO Daniela Marino is quoted as saying in the press release. "At CUTISS, we are committed to advancing treatments that can make a real difference to patients' lives." CUTISS was founded in 2017 as a spin-off of the University of Zurich and is based at the Bio-Technopark Schlieren-Zurich. The denovoSkin manufactured by CUTISS in Switzerland has already been transplanted into more than 60 patients ranging from newborns to adults as part of clinical trials in Europe. ce/hs